IL88204A - Acyl derivatives of 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine and 2'-deoxythymidine and pharmaceutical compositions containing them - Google Patents

Acyl derivatives of 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine and 2'-deoxythymidine and pharmaceutical compositions containing them

Info

Publication number: IL88204A
Authority: IL; Israel
Prior art keywords: acid; carbon atoms; acyl; acyl group; group derived
Prior art date: 1987-10-28

Application number

IL8820488A

Other languages

English (en)

Other versions

IL88204A0 (en

Original Assignee

Pro Neuron Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-10-28

Filing date

1988-10-28

Publication date

1996-06-18

1988-10-28 Application filed by Pro Neuron Inc filed Critical Pro Neuron Inc

1989-06-30 Publication of IL88204A0 publication Critical patent/IL88204A0/xx

1996-06-18 Publication of IL88204A publication Critical patent/IL88204A/en

Links

125000002252 acyl group Chemical group 0.000 title claims abstract description 168
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 title claims description 100
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 title claims description 48
YKBGVTZYEHREMT-KVQBGUIXSA-N 2'-deoxyguanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 YKBGVTZYEHREMT-KVQBGUIXSA-N 0.000 title claims description 26
OLXZPDWKRNYJJZ-UHFFFAOYSA-N 2'-dA Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(CO)O1 OLXZPDWKRNYJJZ-UHFFFAOYSA-N 0.000 title claims description 23
CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 title claims description 22
IQFYYKKMVGJFEH-BIIVOSGPSA-N 2'-deoxythymidine Natural products O=C1NC(=O)C(C)=CN1[C@@H]1O[C@@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-BIIVOSGPSA-N 0.000 title claims description 20
YKBGVTZYEHREMT-UHFFFAOYSA-N 2'-deoxyguanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1CC(O)C(CO)O1 YKBGVTZYEHREMT-UHFFFAOYSA-N 0.000 title claims description 18
VGONTNSXDCQUGY-UHFFFAOYSA-N desoxyinosine Natural products C1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 VGONTNSXDCQUGY-UHFFFAOYSA-N 0.000 title claims description 18
239000008194 pharmaceutical composition Substances 0.000 title claims description 13
CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 title description 16
239000005549 deoxyribonucleoside Substances 0.000 claims abstract description 113
230000002708 enhancing effect Effects 0.000 claims abstract description 14
230000035876 healing Effects 0.000 claims abstract description 9
150000001875 compounds Chemical class 0.000 claims description 97
239000000203 mixture Substances 0.000 claims description 93
125000004432 carbon atom Chemical group C* 0.000 claims description 85
235000014113 dietary fatty acids Nutrition 0.000 claims description 73
229930195729 fatty acid Natural products 0.000 claims description 73
239000000194 fatty acid Substances 0.000 claims description 73
150000004665 fatty acids Chemical class 0.000 claims description 73
229940024606 amino acid Drugs 0.000 claims description 47
235000001014 amino acid Nutrition 0.000 claims description 47
150000001413 amino acids Chemical class 0.000 claims description 47
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 38
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 38
241001465754 Metazoa Species 0.000 claims description 32
150000003839 salts Chemical class 0.000 claims description 23
239000004475 Arginine Substances 0.000 claims description 20
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims description 20
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 20
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 20
239000004472 Lysine Substances 0.000 claims description 20
239000002253 acid Substances 0.000 claims description 20
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 20
229960003121 arginine Drugs 0.000 claims description 20
235000009697 arginine Nutrition 0.000 claims description 20
-1 heterocyclic carboxylic acid Chemical class 0.000 claims description 20
229960003646 lysine Drugs 0.000 claims description 20
235000018977 lysine Nutrition 0.000 claims description 20
230000005855 radiation Effects 0.000 claims description 20
239000004471 Glycine Substances 0.000 claims description 19
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 19
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 19
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 19
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 19
239000004473 Threonine Substances 0.000 claims description 19
229960003136 leucine Drugs 0.000 claims description 19
239000011664 nicotinic acid Substances 0.000 claims description 19
229960003512 nicotinic acid Drugs 0.000 claims description 19
235000001968 nicotinic acid Nutrition 0.000 claims description 19
229960002898 threonine Drugs 0.000 claims description 19
235000008521 threonine Nutrition 0.000 claims description 19
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 18
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 18
125000001424 substituent group Chemical group 0.000 claims description 18
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 17
PHIQHXFUZVPYII-ZCFIWIBFSA-O (R)-carnitinium Chemical compound C[N+](C)(C)C[C@H](O)CC(O)=O PHIQHXFUZVPYII-ZCFIWIBFSA-O 0.000 claims description 17
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 claims description 17
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 17
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 17
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 17
AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims description 17
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 17
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 17
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 17
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 17
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 17
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 17
AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims description 17
UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims description 17
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 17
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 17
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 17
230000002378 acidificating effect Effects 0.000 claims description 17
229960003767 alanine Drugs 0.000 claims description 17
235000004279 alanine Nutrition 0.000 claims description 17
229960005261 aspartic acid Drugs 0.000 claims description 17
235000003704 aspartic acid Nutrition 0.000 claims description 17
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 17
229960004203 carnitine Drugs 0.000 claims description 17
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 17
229960002433 cysteine Drugs 0.000 claims description 17
235000018417 cysteine Nutrition 0.000 claims description 17
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 claims description 17
229960002989 glutamic acid Drugs 0.000 claims description 17
235000013922 glutamic acid Nutrition 0.000 claims description 17
239000004220 glutamic acid Substances 0.000 claims description 17
229910052739 hydrogen Inorganic materials 0.000 claims description 17
239000001257 hydrogen Substances 0.000 claims description 17
229960002591 hydroxyproline Drugs 0.000 claims description 17
229960000310 isoleucine Drugs 0.000 claims description 17
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 17
229960003104 ornithine Drugs 0.000 claims description 17
229960002429 proline Drugs 0.000 claims description 17
229960001153 serine Drugs 0.000 claims description 17
235000004400 serine Nutrition 0.000 claims description 17
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 claims description 17
229960004441 tyrosine Drugs 0.000 claims description 17
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 17
229960004295 valine Drugs 0.000 claims description 17
239000004474 valine Substances 0.000 claims description 17
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 16
229960002885 histidine Drugs 0.000 claims description 16
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims description 16
235000014304 histidine Nutrition 0.000 claims description 16
239000006210 lotion Substances 0.000 claims description 12
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 10
230000005779 cell damage Effects 0.000 claims description 10
239000000725 suspension Substances 0.000 claims description 10
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 9
210000001035 gastrointestinal tract Anatomy 0.000 claims description 9
230000004223 radioprotective effect Effects 0.000 claims description 9
YKYOUMDCQGMQQO-UHFFFAOYSA-L cadmium dichloride Chemical compound Cl[Cd]Cl YKYOUMDCQGMQQO-UHFFFAOYSA-L 0.000 claims description 8
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 8
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 8
231100000252 nontoxic Toxicity 0.000 claims description 8
230000003000 nontoxic effect Effects 0.000 claims description 8
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 8
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 7
UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 claims description 7
150000002431 hydrogen Chemical class 0.000 claims description 7
229960003151 mercaptamine Drugs 0.000 claims description 7
239000003094 microcapsule Substances 0.000 claims description 7
230000001575 pathological effect Effects 0.000 claims description 7
JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 claims description 6
239000008298 dragée Substances 0.000 claims description 6
239000003937 drug carrier Substances 0.000 claims description 6
PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 claims description 6
ZRZPYAHRYAHRCJ-UHFFFAOYSA-N 2-aminoethyl carbamimidothioate molecular bromine Chemical compound BrBr.NCCSC(N)=N ZRZPYAHRYAHRCJ-UHFFFAOYSA-N 0.000 claims description 5
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 5
229920001503 Glucan Polymers 0.000 claims description 5
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
LIFNDDBLJFPEAN-BPSSIEEOSA-N (2s)-4-amino-2-[[(2s)-2-[[2-[[2-[[(2s)-5-amino-2-[[(2s)-2-[[(2s)-6-amino-2-[[(2s)-2-[[(2s)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]hexanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino Chemical compound NC(=O)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@@H]1CCC(=O)N1 LIFNDDBLJFPEAN-BPSSIEEOSA-N 0.000 claims description 4
FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 4
229940006193 2-mercaptoethanesulfonic acid Drugs 0.000 claims description 4
102000016938 Catalase Human genes 0.000 claims description 4
108010053835 Catalase Proteins 0.000 claims description 4
LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 claims description 4
108010024636 Glutathione Proteins 0.000 claims description 4
108010063907 Glutathione Reductase Proteins 0.000 claims description 4
102000006587 Glutathione peroxidase Human genes 0.000 claims description 4
108700016172 Glutathione peroxidases Proteins 0.000 claims description 4
102100036442 Glutathione reductase, mitochondrial Human genes 0.000 claims description 4
102000005720 Glutathione transferase Human genes 0.000 claims description 4
108010070675 Glutathione transferase Proteins 0.000 claims description 4
101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 claims description 4
LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 claims description 4
108010002352 Interleukin-1 Proteins 0.000 claims description 4
PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 claims description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 4
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 4
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 4
229920001491 Lentinan Polymers 0.000 claims description 4
BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
101710185318 Thymic factor Proteins 0.000 claims description 4
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 4
FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 4
YHPLKWQJMAYFCN-UHFFFAOYSA-N WR-1065 Chemical compound NCCCNCCS YHPLKWQJMAYFCN-UHFFFAOYSA-N 0.000 claims description 4
WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 claims description 4
229940022663 acetate Drugs 0.000 claims description 4
OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 claims description 4
FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 4
235000013734 beta-carotene Nutrition 0.000 claims description 4
239000011648 beta-carotene Substances 0.000 claims description 4
TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 claims description 4
229960002747 betacarotene Drugs 0.000 claims description 4
ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 claims description 4
229960003067 cystine Drugs 0.000 claims description 4
GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 claims description 4
YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 claims description 4
229960003180 glutathione Drugs 0.000 claims description 4
QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 claims description 4
239000004310 lactic acid Substances 0.000 claims description 4
235000014655 lactic acid Nutrition 0.000 claims description 4
229940115286 lentinan Drugs 0.000 claims description 4
AIHDCSAXVMAMJH-GFBKWZILSA-N levan Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(CO[C@@H]2[C@H]([C@H](O)[C@@](O)(CO)O2)O)O1 AIHDCSAXVMAMJH-GFBKWZILSA-N 0.000 claims description 4
239000007788 liquid Substances 0.000 claims description 4
229930182817 methionine Natural products 0.000 claims description 4
229960004452 methionine Drugs 0.000 claims description 4
CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 claims description 4
229960000907 methylthioninium chloride Drugs 0.000 claims description 4
239000003471 mutagenic agent Substances 0.000 claims description 4
231100000707 mutagenic chemical Toxicity 0.000 claims description 4
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 4
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 4
229960005190 phenylalanine Drugs 0.000 claims description 4
150000003180 prostaglandins Chemical class 0.000 claims description 4
229910052711 selenium Inorganic materials 0.000 claims description 4
239000011669 selenium Substances 0.000 claims description 4
239000000829 suppository Substances 0.000 claims description 4
229960001295 tocopherol Drugs 0.000 claims description 4
235000010384 tocopherol Nutrition 0.000 claims description 4
229930003799 tocopherol Natural products 0.000 claims description 4
239000011732 tocopherol Substances 0.000 claims description 4
229960004799 tryptophan Drugs 0.000 claims description 4
235000019155 vitamin A Nutrition 0.000 claims description 4
239000011719 vitamin A Substances 0.000 claims description 4
229940045997 vitamin a Drugs 0.000 claims description 4
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 4
OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 claims description 4
WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 claims description 3
229910021380 Manganese Chloride Inorganic materials 0.000 claims description 3
GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 claims description 3
229920002305 Schizophyllan Polymers 0.000 claims description 3
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
102000019197 Superoxide Dismutase Human genes 0.000 claims description 3
108010012715 Superoxide dismutase Proteins 0.000 claims description 3
DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 claims description 3
229960004050 aminobenzoic acid Drugs 0.000 claims description 3
229920001577 copolymer Polymers 0.000 claims description 3
239000011565 manganese chloride Substances 0.000 claims description 3
235000002867 manganese chloride Nutrition 0.000 claims description 3
230000003505 mutagenic effect Effects 0.000 claims description 3
229960005010 orotic acid Drugs 0.000 claims description 3
239000005711 Benzoic acid Substances 0.000 claims description 2
235000010233 benzoic acid Nutrition 0.000 claims description 2
125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
230000011132 hemopoiesis Effects 0.000 claims description 2
229940102223 injectable solution Drugs 0.000 claims description 2
230000007102 metabolic function Effects 0.000 claims description 2
229940100613 topical solution Drugs 0.000 claims description 2
GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 claims 4
WHBMMWSBFZVSSR-UHFFFAOYSA-N 3-hydroxybutyric acid Chemical compound CC(O)CC(O)=O WHBMMWSBFZVSSR-UHFFFAOYSA-N 0.000 claims 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 4
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims 4
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims 4
NXHRVUSMADPZLY-VKKIDBQXSA-N 2-aminoethanethiol;(2s,3s)-1,4-bis(sulfanyl)butane-2,3-diol Chemical compound NCCS.SC[C@@H](O)[C@H](O)CS NXHRVUSMADPZLY-VKKIDBQXSA-N 0.000 claims 2
GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims 2
239000001530 fumaric acid Substances 0.000 claims 2
229960002598 fumaric acid Drugs 0.000 claims 2
235000011087 fumaric acid Nutrition 0.000 claims 2
AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims 2
235000019136 lipoic acid Nutrition 0.000 claims 2
229940055726 pantothenic acid Drugs 0.000 claims 2
239000011713 pantothenic acid Substances 0.000 claims 2
235000019161 pantothenic acid Nutrition 0.000 claims 2
229940107700 pyruvic acid Drugs 0.000 claims 2
229960002663 thioctic acid Drugs 0.000 claims 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 2
DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims 1
229920000642 polymer Polymers 0.000 claims 1
210000001185 bone marrow Anatomy 0.000 abstract description 9
239000003814 drug Substances 0.000 abstract description 2
238000004519 manufacturing process Methods 0.000 abstract 1
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 65
239000002777 nucleoside Substances 0.000 description 39
210000001519 tissue Anatomy 0.000 description 39
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 32
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 29
229940104230 thymidine Drugs 0.000 description 29
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 28
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 27
125000003835 nucleoside group Chemical group 0.000 description 26
238000011282 treatment Methods 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
102000053602 DNA Human genes 0.000 description 22
210000004185 liver Anatomy 0.000 description 22
150000003833 nucleoside derivatives Chemical class 0.000 description 22
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 20
241000699670 Mus sp. Species 0.000 description 17
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 16
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 16
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 15
230000015556 catabolic process Effects 0.000 description 14
239000003921 oil Substances 0.000 description 14
235000019198 oils Nutrition 0.000 description 14
238000002360 preparation method Methods 0.000 description 14
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
102000004190 Enzymes Human genes 0.000 description 13
108090000790 Enzymes Proteins 0.000 description 13
239000002904 solvent Substances 0.000 description 13
230000004083 survival effect Effects 0.000 description 13
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
230000006378 damage Effects 0.000 description 12
230000000694 effects Effects 0.000 description 12
238000000034 method Methods 0.000 description 12
206010052428 Wound Diseases 0.000 description 10
208000027418 Wounds and injury Diseases 0.000 description 10
241000700159 Rattus Species 0.000 description 9
150000008065 acid anhydrides Chemical class 0.000 description 9
239000003795 chemical substances by application Substances 0.000 description 9
230000020176 deacylation Effects 0.000 description 9
238000005947 deacylation reaction Methods 0.000 description 9
238000006731 degradation reaction Methods 0.000 description 8
238000001727 in vivo Methods 0.000 description 8
230000005865 ionizing radiation Effects 0.000 description 8
238000011084 recovery Methods 0.000 description 8
238000011069 regeneration method Methods 0.000 description 8
150000003855 acyl compounds Chemical class 0.000 description 7
238000005917 acylation reaction Methods 0.000 description 7
239000011541 reaction mixture Substances 0.000 description 7
230000008929 regeneration Effects 0.000 description 7
230000008439 repair process Effects 0.000 description 7
230000002459 sustained effect Effects 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
CKTSBUTUHBMZGZ-ULQXZJNLSA-N 4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-tritiopyrimidin-2-one Chemical compound O=C1N=C(N)C([3H])=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-ULQXZJNLSA-N 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
239000007924 injection Substances 0.000 description 6
238000002347 injection Methods 0.000 description 6
235000017557 sodium bicarbonate Nutrition 0.000 description 6
229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
239000007787 solid Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
231100000419 toxicity Toxicity 0.000 description 6
230000001988 toxicity Effects 0.000 description 6
230000029663 wound healing Effects 0.000 description 6
108090000371 Esterases Proteins 0.000 description 5
206010073306 Exposure to radiation Diseases 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
RGVBNBFNSBMXID-QJPTWQEYSA-N [(2r,3s,5r)-3-acetyloxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methyl acetate Chemical compound C1[C@H](OC(C)=O)[C@@H](COC(=O)C)O[C@H]1N1C(=O)NC(=O)C(C)=C1 RGVBNBFNSBMXID-QJPTWQEYSA-N 0.000 description 5
LTKCXZGFJFAPLY-OERIEOFYSA-N [1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-2-oxopyrimidin-4-yl]azanium;chloride Chemical compound Cl.O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 LTKCXZGFJFAPLY-OERIEOFYSA-N 0.000 description 5
230000010933 acylation Effects 0.000 description 5
230000008901 benefit Effects 0.000 description 5
239000002775 capsule Substances 0.000 description 5
150000001735 carboxylic acids Chemical class 0.000 description 5
238000006243 chemical reaction Methods 0.000 description 5
238000004587 chromatography analysis Methods 0.000 description 5
150000002148 esters Chemical class 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 4
102000055025 Adenosine deaminases Human genes 0.000 description 4
108010010803 Gelatin Proteins 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010028980 Neoplasm Diseases 0.000 description 4
101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 4
102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 4
101710132082 Pyrimidine/purine nucleoside phosphorylase Proteins 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
206010072170 Skin wound Diseases 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
102000013537 Thymidine Phosphorylase Human genes 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
201000011510 cancer Diseases 0.000 description 4
210000004027 cell Anatomy 0.000 description 4
150000001991 dicarboxylic acids Chemical class 0.000 description 4
230000007515 enzymatic degradation Effects 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000009472 formulation Methods 0.000 description 4
230000006870 function Effects 0.000 description 4
239000008273 gelatin Substances 0.000 description 4
229920000159 gelatin Polymers 0.000 description 4
235000019322 gelatine Nutrition 0.000 description 4
235000011852 gelatine desserts Nutrition 0.000 description 4
231100000518 lethal Toxicity 0.000 description 4
230000001665 lethal effect Effects 0.000 description 4
229940040511 liver extract Drugs 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
210000004379 membrane Anatomy 0.000 description 4
239000012528 membrane Substances 0.000 description 4
239000002207 metabolite Substances 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
230000001737 promoting effect Effects 0.000 description 4
238000001959 radiotherapy Methods 0.000 description 4
150000003335 secondary amines Chemical class 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
238000010561 standard procedure Methods 0.000 description 4
210000000130 stem cell Anatomy 0.000 description 4
230000017423 tissue regeneration Effects 0.000 description 4
238000011200 topical administration Methods 0.000 description 4
150000003626 triacylglycerols Chemical class 0.000 description 4
XPLAPZRLDKXDQQ-APTVDZGQSA-N 1-[(2r,4s,5r)-4-acetyl-4-hydroxy-5-(1-hydroxy-2-oxopropyl)oxolan-2-yl]-4-aminopyrimidin-2-one Chemical compound C1[C@](C(C)=O)(O)[C@@H](C(O)C(=O)C)O[C@H]1N1C(=O)N=C(N)C=C1 XPLAPZRLDKXDQQ-APTVDZGQSA-N 0.000 description 3
208000032484 Accidental exposure to product Diseases 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108090000531 Amidohydrolases Proteins 0.000 description 3
102000004092 Amidohydrolases Human genes 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
231100000818 accidental exposure Toxicity 0.000 description 3
230000032683 aging Effects 0.000 description 3
125000003277 amino group Chemical group 0.000 description 3
150000008064 anhydrides Chemical class 0.000 description 3
230000000118 anti-neoplastic effect Effects 0.000 description 3
230000000840 anti-viral effect Effects 0.000 description 3
239000002246 antineoplastic agent Substances 0.000 description 3
230000009286 beneficial effect Effects 0.000 description 3
230000001413 cellular effect Effects 0.000 description 3
239000002962 chemical mutagen Substances 0.000 description 3
238000002512 chemotherapy Methods 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
238000000605 extraction Methods 0.000 description 3
239000010685 fatty oil Substances 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
239000005457 ice water Substances 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000006872 improvement Effects 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000002773 nucleotide Substances 0.000 description 3
125000003729 nucleotide group Chemical group 0.000 description 3
210000000056 organ Anatomy 0.000 description 3
125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
239000000546 pharmaceutical excipient Substances 0.000 description 3
125000000714 pyrimidinyl group Chemical group 0.000 description 3
125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
239000003381 stabilizer Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
230000001629 suppression Effects 0.000 description 3
238000003786 synthesis reaction Methods 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
BCNZYOJHNLTNEZ-UHFFFAOYSA-N tert-butyldimethylsilyl chloride Chemical compound CC(C)(C)[Si](C)(C)Cl BCNZYOJHNLTNEZ-UHFFFAOYSA-N 0.000 description 3
UMZSVRZKZORKOC-FPKZOZHISA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;hydrochloride Chemical compound Cl.C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 UMZSVRZKZORKOC-FPKZOZHISA-N 0.000 description 2
239000002126 C01EB10 - Adenosine Substances 0.000 description 2
102100026846 Cytidine deaminase Human genes 0.000 description 2
108010031325 Cytidine deaminase Proteins 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
102000000589 Interleukin-1 Human genes 0.000 description 2
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
108091005804 Peptidases Proteins 0.000 description 2
102000035195 Peptidases Human genes 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
206010042496 Sunburn Diseases 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
DZYFXJMIESZKHH-HBNTYKKESA-N [(2r,3s,5r)-5-(6-aminopurin-9-yl)-3-hydroxyoxolan-2-yl]methyl pentanoate Chemical compound C1[C@H](O)[C@@H](COC(=O)CCCC)O[C@H]1N1C2=NC=NC(N)=C2N=C1 DZYFXJMIESZKHH-HBNTYKKESA-N 0.000 description 2
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
229960005305 adenosine Drugs 0.000 description 2
238000010171 animal model Methods 0.000 description 2
229940034982 antineoplastic agent Drugs 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
210000004369 blood Anatomy 0.000 description 2
239000008280 blood Substances 0.000 description 2
244000309464 bull Species 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000024245 cell differentiation Effects 0.000 description 2
230000004663 cell proliferation Effects 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
230000009615 deamination Effects 0.000 description 2
238000006481 deamination reaction Methods 0.000 description 2
230000007812 deficiency Effects 0.000 description 2
239000007857 degradation product Substances 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000004069 differentiation Effects 0.000 description 2
238000001035 drying Methods 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
239000000945 filler Substances 0.000 description 2
210000004051 gastric juice Anatomy 0.000 description 2
239000008187 granular material Substances 0.000 description 2
ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
150000002430 hydrocarbons Chemical class 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
239000008101 lactose Substances 0.000 description 2
238000004811 liquid chromatography Methods 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
230000037353 metabolic pathway Effects 0.000 description 2
229960000485 methotrexate Drugs 0.000 description 2
231100000956 nontoxicity Toxicity 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
239000002504 physiological saline solution Substances 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000008569 process Effects 0.000 description 2
238000012545 processing Methods 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
235000019833 protease Nutrition 0.000 description 2
125000006239 protecting group Chemical group 0.000 description 2
238000002601 radiography Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
229920006395 saturated elastomer Polymers 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
239000000758 substrate Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000002511 suppository base Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
231100001274 therapeutic index Toxicity 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical class [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
239000003981 vehicle Substances 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
PILPQAMQDMXSBY-NSHDSACASA-N (2s)-6-amino-2-[bis[(2-methylpropan-2-yl)oxycarbonyl]amino]hexanoic acid Chemical compound CC(C)(C)OC(=O)N(C(=O)OC(C)(C)C)[C@H](C(O)=O)CCCCN PILPQAMQDMXSBY-NSHDSACASA-N 0.000 description 1
ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
NDWNDWUSEHILES-SXMVTHIZSA-N 1-[(2s,4s,5r)-2-(6-aminopurin-9-yl)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]ethanone Chemical compound C1=NC2=C(N)N=CN=C2N1[C@@]1(C(=O)C)C[C@H](O)[C@@H](CO)O1 NDWNDWUSEHILES-SXMVTHIZSA-N 0.000 description 1
NRRVFNZVWGPGQG-SBMIAAHKSA-N 1-[(2s,4s,5r)-2-acetyl-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound C1=C(C)C(=O)NC(=O)N1[C@@]1(C(=O)C)C[C@H](O)[C@@H](CO)O1 NRRVFNZVWGPGQG-SBMIAAHKSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
OLXZPDWKRNYJJZ-RRKCRQDMSA-N 2'-deoxyadenosine Chemical class C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 OLXZPDWKRNYJJZ-RRKCRQDMSA-N 0.000 description 1
VGONTNSXDCQUGY-RRKCRQDMSA-N 2'-deoxyinosine Chemical group C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC2=O)=C2N=C1 VGONTNSXDCQUGY-RRKCRQDMSA-N 0.000 description 1
VWUVOHLUOBJYHD-UHFFFAOYSA-N 2-[tert-butyl(dimethyl)silyl]oxypropanoic acid Chemical compound OC(=O)C(C)O[Si](C)(C)C(C)(C)C VWUVOHLUOBJYHD-UHFFFAOYSA-N 0.000 description 1
ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical group N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
206010065553 Bone marrow failure Diseases 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
241000237074 Centris Species 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
102100038076 DNA dC->dU-editing enzyme APOBEC-3G Human genes 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
206010063560 Excessive granulation tissue Diseases 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
229940123457 Free radical scavenger Drugs 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
229930010555 Inosine Natural products 0.000 description 1
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108010002350 Interleukin-2 Proteins 0.000 description 1
208000034693 Laceration Diseases 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
102000009423 Nucleoside Deaminases Human genes 0.000 description 1
108010034093 Nucleoside Deaminases Proteins 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
102100036286 Purine nucleoside phosphorylase Human genes 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
208000002847 Surgical Wound Diseases 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
GGNBLGBTFLKGQP-QZNHQXDQSA-N [(2r,3s,5r)-5-(4-amino-2-oxopyrimidin-1-yl)-3-hydroxyoxolan-2-yl]methyl hexadecanoate Chemical compound C1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(N)C=C1 GGNBLGBTFLKGQP-QZNHQXDQSA-N 0.000 description 1
SMJSFYHBFITINL-WDTRASESSA-N [(2r,3s,5r)-5-[4-[[(2s)-2,6-diaminohexanoyl]amino]-2-oxopyrimidin-1-yl]-3-hydroxyoxolan-2-yl]methyl hexadecanoate Chemical compound C1[C@H](O)[C@@H](COC(=O)CCCCCCCCCCCCCCC)O[C@H]1N1C(=O)N=C(NC(=O)[C@@H](N)CCCCN)C=C1 SMJSFYHBFITINL-WDTRASESSA-N 0.000 description 1
ZEEBGORNQSEQBE-UHFFFAOYSA-N [2-(3-phenylphenoxy)-6-(trifluoromethyl)pyridin-4-yl]methanamine Chemical compound C1(=CC(=CC=C1)OC1=NC(=CC(=C1)CN)C(F)(F)F)C1=CC=CC=C1 ZEEBGORNQSEQBE-UHFFFAOYSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
238000005299 abrasion Methods 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
230000001133 acceleration Effects 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
229960000583 acetic acid Drugs 0.000 description 1
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
229940081735 acetylcellulose Drugs 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000005585 adamantoate group Chemical group 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
150000003835 adenosine derivatives Chemical class 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
150000001279 adipic acids Chemical class 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
YVPYQUNUQOZFHG-UHFFFAOYSA-N amidotrizoic acid Chemical compound CC(=O)NC1=C(I)C(NC(C)=O)=C(I)C(C(O)=O)=C1I YVPYQUNUQOZFHG-UHFFFAOYSA-N 0.000 description 1
230000001195 anabolic effect Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
229940053200 antiepileptics fatty acid derivative Drugs 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
239000000010 aprotic solvent Substances 0.000 description 1
239000006286 aqueous extract Substances 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
150000004982 aromatic amines Chemical class 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
238000002306 biochemical method Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
229920013641 bioerodible polymer Polymers 0.000 description 1
238000010241 blood sampling Methods 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
239000000872 buffer Substances 0.000 description 1
229960002092 busulfan Drugs 0.000 description 1
YHASWHZGWUONAO-UHFFFAOYSA-N butanoyl butanoate Chemical compound CCCC(=O)OC(=O)CCC YHASWHZGWUONAO-UHFFFAOYSA-N 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
150000007942 carboxylates Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001925 catabolic effect Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
230000000973 chemotherapeutic effect Effects 0.000 description 1
150000001805 chlorine compounds Chemical class 0.000 description 1
230000001684 chronic effect Effects 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011281 clinical therapy Methods 0.000 description 1
239000003240 coconut oil Substances 0.000 description 1
235000019864 coconut oil Nutrition 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
229960004397 cyclophosphamide Drugs 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000006735 deficit Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
108010083618 deoxycytidine deaminase Proteins 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000001784 detoxification Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000000378 dietary effect Effects 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
238000004980 dosimetry Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000003304 gavage Methods 0.000 description 1
239000012362 glacial acetic acid Substances 0.000 description 1
229940049906 glutamate Drugs 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
150000002311 glutaric acids Chemical class 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
210000001126 granulation tissue Anatomy 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
238000000227 grinding Methods 0.000 description 1
239000001963 growth medium Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
210000003958 hematopoietic stem cell Anatomy 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical group CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 1
235000011167 hydrochloric acid Nutrition 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
229960003786 inosine Drugs 0.000 description 1
229940079322 interferon Drugs 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
210000004731 jugular vein Anatomy 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000004922 lacquer Substances 0.000 description 1
150000002605 large molecules Chemical class 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000005228 liver tissue Anatomy 0.000 description 1
230000007774 longterm Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000004962 mammalian cell Anatomy 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
238000006241 metabolic reaction Methods 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
231100000324 minimal toxicity Toxicity 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
210000004165 myocardium Anatomy 0.000 description 1
MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
102000039446 nucleic acids Human genes 0.000 description 1
108020004707 nucleic acids Proteins 0.000 description 1
150000007523 nucleic acids Chemical class 0.000 description 1
108010009099 nucleoside phosphorylase Proteins 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
HGASFNYMVGEKTF-UHFFFAOYSA-N octan-1-ol;hydrate Chemical compound O.CCCCCCCCO HGASFNYMVGEKTF-UHFFFAOYSA-N 0.000 description 1
125000002801 octanoyl group Chemical group C(CCCCCCC)(=O)* 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000010494 opalescence Effects 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
239000003791 organic solvent mixture Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
238000012753 partial hepatectomy Methods 0.000 description 1
238000005192 partition Methods 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
150000003016 phosphoric acids Chemical class 0.000 description 1
XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
239000000049 pigment Substances 0.000 description 1
125000005547 pivalate group Chemical group 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000002028 premature Effects 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
229940002612 prodrug Drugs 0.000 description 1
239000000651 prodrug Substances 0.000 description 1
239000000047 product Substances 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
239000002212 purine nucleoside Substances 0.000 description 1
125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
239000002516 radical scavenger Substances 0.000 description 1
230000009467 reduction Effects 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
230000036573 scar formation Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000007901 soft capsule Substances 0.000 description 1
239000012439 solid excipient Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000011550 stock solution Substances 0.000 description 1
150000003444 succinic acids Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
230000000475 sunscreen effect Effects 0.000 description 1
239000000516 sunscreening agent Substances 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical group CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000012049 topical pharmaceutical composition Substances 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
125000005270 trialkylamine group Chemical group 0.000 description 1
229940078499 tricalcium phosphate Drugs 0.000 description 1
235000019731 tricalcium phosphate Nutrition 0.000 description 1
229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Saccharide Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Cosmetics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL8820488A 1987-10-28 1988-10-28 Acyl derivatives of 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine and 2'-deoxythymidine and pharmaceutical compositions containing them IL88204A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US11592387A	1987-10-28	1987-10-28

Publications (2)

Publication Number	Publication Date
IL88204A0 IL88204A0 (en)	1989-06-30
IL88204A true IL88204A (en)	1996-06-18

Family

ID=22364166

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL8820488A IL88204A (en)	1987-10-28	1988-10-28	Acyl derivatives of 2'-deoxyadenosine, 2'-deoxyguanosine, 2'-deoxycytidine and 2'-deoxythymidine and pharmaceutical compositions containing them

Country Status (15)

Country	Link
US (1)	US6020320A (sv)
EP (2)	EP0355131B1 (sv)
JP (2)	JP2637534B2 (sv)
KR (1)	KR890701609A (sv)
AT (2)	ATE142221T1 (sv)
CA (1)	CA1329932C (sv)
DE (2)	DE3856557T2 (sv)
DK (1)	DK174400B1 (sv)
FI (2)	FI91764C (sv)
HK (1)	HK1004854A1 (sv)
IL (1)	IL88204A (sv)
IN (1)	IN167609B (sv)
NO (1)	NO174392C (sv)
WO (1)	WO1989003838A1 (sv)
ZA (1)	ZA888083B (sv)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5470838A (en)	1987-10-28	1995-11-28	Pro-Neuron, Inc.	Method of delivering exogenous uridine or cytidine using acylated uridine or cytidine
US6743782B1 (en) *	1987-10-28	2004-06-01	Wellstat Therapeutics Corporation	Acyl deoxyribonucleoside derivatives and uses thereof
US5736531A (en)	1987-10-28	1998-04-07	Pro-Neuron, Inc.	Compositions of chemotherapeutic agent or antiviral agent with acylated pyrimidine nucleosides
US5968914A (en) *	1987-10-28	1999-10-19	Pro-Neuron, Inc.	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US7776838B1 (en)	1987-10-28	2010-08-17	Wellstat Therapeutics Corporation	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
US5691320A (en) *	1987-10-28	1997-11-25	Pro-Neuron, Inc.	Acylated pyrimidine nucleosides for treatment of systemic inflammation and inflammatory hepatitis
US6060459A (en)	1987-10-28	2000-05-09	Pro-Neuron, Inc.	Enhancing blood cell count with oxypurine nucleosides
US6329350B1 (en) *	1987-10-28	2001-12-11	Pro-Neuron, Inc.	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
IE980216A1 (en) *	1989-04-17	2000-02-23	Scotia Holdings Plc	Anti-virals
CA2444071C (en) *	1991-02-08	2008-10-07	Wellstat Therapeutics Corporation	Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
CA2111571C (en) *	1991-07-05	2005-08-23	Reid W. Von Borstel	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
GB2260319B (en) *	1991-10-07	1995-12-06	Norsk Hydro As	Acyl derivatives of nucleosides and nucleoside analogues having anti-viral activity
ATE282627T1 (de) *	1992-12-08	2004-12-15	Wellstat Therapeutics Corp	Pyrimidinnukleotid-vorläufer zur behandlung entzündlicher hepatitis
US5641758A (en) *	1993-11-10	1997-06-24	Kluge; Michael	Cytarabine derivatives, the preparation and use thereof
JP4408450B2 (ja)	1994-07-01	2010-02-03	ウェルスタットセラピューティクスコーポレイション	全身性炎症および炎症性肝炎の処置のためのピリミジンヌクレオチド前駆体
EP0882734B1 (en) *	1997-06-02	2009-08-26	F. Hoffmann-La Roche Ag	5'-Deoxy-cytidine derivatives
US20020006913A1 (en)	1997-11-04	2002-01-17	Von Borstel Reid W.	Antimutagenic compositions for treatment and prevention of photodamage to skin
AU2090099A (en) *	1997-12-16	1999-07-05	William Darwin Garner	Reduction of uv induced skin cancer by topical amines
US6444652B1 (en)	1998-08-10	2002-09-03	Novirio Pharmaceuticals Limited	β-L-2'-deoxy-nucleosides for the treatment of hepatitis B
PT1431304E (pt)	1998-08-10	2015-03-09	Novartis Ag	Beta-l-2'-desoxi-nucleosidos para o tratamento da hepatite b
PT1171137E (pt)	1999-02-23	2008-03-17	Univ California	Utilização de triacetiluridina para o tratamento de perturbações mitocondriais
US6576619B2 (en) *	1999-05-24	2003-06-10	Cv Therapeutics, Inc.	Orally active A1 adenosine receptor agonists
US6787526B1 (en)	2000-05-26	2004-09-07	Idenix Pharmaceuticals, Inc.	Methods of treating hepatitis delta virus infection with β-L-2′-deoxy-nucleosides
US6875751B2 (en)	2000-06-15	2005-04-05	Idenix Pharmaceuticals, Inc.	3′-prodrugs of 2′-deoxy-β-L-nucleosides
DE10117615A1 (de) *	2001-04-07	2002-10-10	Max Delbrueck Centrum	Verwendung von Nucleosiden, Nucleobasen und deren Derivaten zur verbesserten Gewinnung von adulten Stammzellen
TWI244393B (en)	2002-08-06	2005-12-01	Idenix Pharmaceuticals Inc	Crystalline and amorphous forms of beta-L-2'-deoxythymidine
CA2498731C (en)	2002-09-13	2012-10-30	Idenix (Cayman) Limited	.beta.-l-2'-deoxynucleosides for the treatment of resistant hbv strains and combination therapies
WO2009045655A2 (en)	2007-08-16	2009-04-09	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Compositions containing purine nucleosides and manganese and their uses
WO2010090723A2 (en) *	2009-02-04	2010-08-12	University Of Georgia Research Foundation, Inc.	Methods of inhibiting fibrogenesis and treating fibrotic disease
CA2797716C (en)	2010-04-29	2018-09-11	The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc.	Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses
US9446064B2 (en)	2013-03-14	2016-09-20	Epizyme, Inc.	Combination therapy for treating cancer
AU2021202658A1 (en)	2021-04-28	2022-11-17	Fondazione Telethon	Gene therapy

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3847898A (en) *	1969-05-27	1974-11-12	Upjohn Co	N4-trihaloethoxy carbonyl arabino-furanosyl cytosine 5'-esters
US3585188A (en) *	1969-06-16	1971-06-15	Takeda Chemical Industries Ltd	Process for producing 2'-deoxyuridine
DE1941942A1 (de) *	1969-08-18	1971-03-04	Sylven Bengt Prof Dr	Neues pharmazeutisches Mittel
FR2096712A1 (en) *	1970-06-29	1972-02-25	Giraux Georges	Steroid/b group vitamin compsns - for prevention and treatment of skin-photosensitivity disorders
US3894000A (en) *	1971-01-27	1975-07-08	Upjohn Co	Ara-cytidine derivatives and process of preparation
US3975367A (en) *	1971-06-08	1976-08-17	The Upjohn Company	Arabinofuranosyl N4 -aminoacyl cytosine containing compounds
DE2147094A1 (de) *	1971-09-21	1973-04-05	Robugen Gmbh	Virostatisch wirksames arzneimittel
US3991045A (en) *	1973-05-30	1976-11-09	Asahi Kasei Kogyo Kabushiki Kaisha	N4 -acylarabinonucleosides
US4048432A (en) *	1976-05-17	1977-09-13	Parke, Davis & Company	9-(3,5-Di-O-acyl-β-D-arabinofuranosyl)adenine compounds and method for their production
FR2358155A1 (fr) *	1976-07-15	1978-02-10	Lapinet Eugene	Composition pour le traitement et la prevention de l'irritation et de l'inflammation de la peau, de l'oeil et des muqueuses
US4675189A (en) *	1980-11-18	1987-06-23	Syntex (U.S.A.) Inc.	Microencapsulation of water soluble active polypeptides
JPS5791994A (en) *	1980-11-26	1982-06-08	Fuji Kagaku Kogyo Kk	5'-o-(n-alkylcarbamoylalanyl)-5-fluorouridine and its preparation
DE3100478A1 (de)	1981-01-09	1982-08-12	Dr. Thilo & Co GmbH, 8021 Sauerlach	5'ester von pyrimidinnucleosiden mit antiviraler wirksamkeit, verfahren zur herstellung und daraus hergestellte arzneimittel
JPS57156418A (en) *	1981-03-19	1982-09-27	Sumitomo Chem Co Ltd	Carcinostatic
JPS5849315A (ja) *	1981-09-18	1983-03-23	Mitsui Pharmaceut Inc	抗腫瘍剤
JPS58167589A (ja) *	1982-03-26	1983-10-03	Nissan Chem Ind Ltd	ピラゾ−ル誘導体、その製法および該誘導体を含有する除草剤
JPS58167598A (ja) *	1982-03-29	1983-10-03	Tanabe Seiyaku Co Ltd	アデノシン誘導体及びその製法
FR2536278A1 (fr) *	1982-11-18	1984-05-25	Dupont Michele	Nouvelle composition therapeutique utile notamment pour la cicatrisation des plaies
DE3319282A1 (de) *	1983-05-27	1984-11-29	Gödecke AG, 1000 Berlin	Verwendung von adenosin bei der behandlung von herpes
JPS59219235A (ja) *	1983-05-30	1984-12-10	Mitsui Toatsu Chem Inc	消化性潰瘍用剤
DE3481191D1 (de) *	1983-07-20	1990-03-08	Teijin Ltd	Antineoplastisches mittel.
JPS6028929A (ja) *	1983-07-28	1985-02-14	Hokuriku Seiyaku Co Ltd	２’−デオキシグアノシンを有効成分とする消化性潰瘍治療剤
JPS6064907A (ja) *	1983-09-17	1985-04-13	Risuburan Prod:Kk	水性ゲル状化粧料
JPS60126220A (ja) *	1983-12-09	1985-07-05	Otsuka Pharmaceut Factory Inc	核酸成分組成物
FR2556727B1 (fr) *	1983-12-19	1990-01-19	Biostabilex Labo Pharma	Nouvelles compositions therapeutiques a base d'adn a haut poids moleculaire et leur procede de preparation
JPS60174797A (ja)	1984-02-21	1985-09-09	Funai Corp	Ν−アロイルチミジン誘導体ならびに抗腫瘍活性物質の毒性低下剤
EP0227844B1 (en) *	1985-07-22	1992-05-13	Teijin Limited	Antiviral drug
US4762823A (en) *	1985-10-16	1988-08-09	Sloan-Kettering Institute For Cancer Research	Nucleosides of 5-monofluoromethyluracil and 5-difluoromethyluracil
ATE146077T1 (de) *	1986-09-22	1996-12-15	Janssen Pharmaceutica Nv	Serotonin-antagonisten zur behandlung von wunden
US4758533A (en) *	1987-09-22	1988-07-19	Xmr Inc.	Laser planarization of nonrefractory metal during integrated circuit fabrication
US5246708A (en) *	1987-10-28	1993-09-21	Pro-Neuron, Inc.	Methods for promoting wound healing with deoxyribonucleosides
JP2638949B2 (ja) *	1988-07-06	1997-08-06	トヨタ自動車株式会社	誘導電導機の制御方法
JPH0628929A (ja) *	1992-07-09	1994-02-04	Fujikura Ltd	絶縁電線
JPH0634913A (ja) *	1992-07-15	1994-02-10	Oki Electric Ind Co Ltd	密着イメージセンサの光学構成方法
JP3251060B2 (ja) *	1992-08-18	2002-01-28	電気化学工業株式会社	窒化珪素粉末
JPH06123917A (ja) *	1992-08-24	1994-05-06	Fuji Photo Film Co Ltd	写真作製装置
JP3454951B2 (ja) *	1994-12-12	2003-10-06	株式会社半導体エネルギー研究所	半導体装置の作製方法

1988
- 1988-10-27 EP EP88910239A patent/EP0355131B1/en not_active Expired - Lifetime
- 1988-10-27 ZA ZA888083A patent/ZA888083B/xx unknown
- 1988-10-27 DE DE3856557T patent/DE3856557T2/de not_active Expired - Fee Related
- 1988-10-27 WO PCT/US1988/003824 patent/WO1989003838A1/en active IP Right Grant
- 1988-10-27 DE DE3855513T patent/DE3855513T2/de not_active Expired - Fee Related
- 1988-10-27 KR KR1019890701195A patent/KR890701609A/ko not_active IP Right Cessation
- 1988-10-27 EP EP95203050A patent/EP0712629B1/en not_active Expired - Lifetime
- 1988-10-27 AT AT88910239T patent/ATE142221T1/de not_active IP Right Cessation
- 1988-10-27 JP JP63509388A patent/JP2637534B2/ja not_active Expired - Fee Related
- 1988-10-27 AT AT95203050T patent/ATE243039T1/de not_active IP Right Cessation
- 1988-10-27 CA CA000581430A patent/CA1329932C/en not_active Expired - Fee Related
- 1988-10-28 IL IL8820488A patent/IL88204A/en not_active IP Right Cessation
- 1988-10-28 IN IN754/MAS/88A patent/IN167609B/en unknown
1989
- 1989-06-26 FI FI893100A patent/FI91764C/sv not_active IP Right Cessation
- 1989-06-26 NO NO892642A patent/NO174392C/no not_active IP Right Cessation
- 1989-06-27 DK DK198903180A patent/DK174400B1/da not_active IP Right Cessation
1993
- 1993-11-17 US US08/153,163 patent/US6020320A/en not_active Expired - Fee Related
1994
- 1994-03-16 FI FI941245A patent/FI97891C/sv not_active IP Right Cessation
- 1994-10-26 JP JP6299158A patent/JP2764014B2/ja not_active Expired - Lifetime
1998
- 1998-04-29 HK HK98103631A patent/HK1004854A1/xx not_active IP Right Cessation

Also Published As

Publication number	Publication date
DE3856557T2 (de)	2004-06-03
NO174392B (no)	1994-01-17
EP0712629B1 (en)	2003-06-18
DK174400B1 (da)	2003-02-10
NO892642L (no)	1989-08-24
ZA888083B (en)	1990-06-27
FI91764B (sv)	1994-04-29
ATE243039T1 (de)	2003-07-15
DE3855513D1 (de)	1996-10-10
JP2764014B2 (ja)	1998-06-11
EP0355131A4 (en)	1990-12-05
DK318089D0 (da)	1989-06-27
JPH07267981A (ja)	1995-10-17
NO174392C (no)	1994-04-27
FI941245A (sv)	1994-03-16
EP0355131B1 (en)	1996-09-04
FI91764C (sv)	1994-08-10
CA1329932C (en)	1994-05-31
FI97891B (sv)	1996-11-29
WO1989003838A1 (en)	1989-05-05
FI941245A0 (sv)	1994-03-16
FI893100A (sv)	1989-06-26
ATE142221T1 (de)	1996-09-15
DE3856557D1 (de)	2003-07-24
HK1004854A1 (en)	1998-12-11
JPH02500373A (ja)	1990-02-08
FI97891C (sv)	1997-03-10
EP0712629A1 (en)	1996-05-22
EP0355131A1 (en)	1990-02-28
JP2637534B2 (ja)	1997-08-06
US6020320A (en)	2000-02-01
IN167609B (sv)	1990-11-24
DE3855513T2 (de)	1997-01-09
FI893100A0 (sv)	1989-06-26
KR890701609A (ko)	1989-12-21
IL88204A0 (en)	1989-06-30
DK318089A (da)	1989-08-28
NO892642D0 (no)	1989-06-26

Publication	Publication Date	Title
EP0712629B1 (en)	2003-06-18	Acyl deoxyribonucleoside derivatives and uses thereof
US6020322A (en)	2000-02-01	Acyl deoxyribonucleoside derivatives and uses thereof
CA2111571C (en)	2005-08-23	Treatment of chemotherapeutic agent and antiviral agent toxicity with acylated pyrimidine nucleosides
JP2003201240A (ja)	2003-07-18	アシル化ピリミジンヌクレオシドによる化学療法剤および抗ウイルス剤の毒性を減少させる方法
JP3885006B2 (ja)	2007-02-21	造血改善のためのオキシプリンヌクレオシド、およびそれらの同族体、ならびにそのアシル誘導体
US6348451B1 (en)	2002-02-19	Acyl deoxyribonucleoside derivatives and uses thereof
CA2150940C (en)	2007-08-21	Pyrimidine nucleotide precursors for treatment of systemic inflammation and inflammatory hepatitis
US7169765B1 (en)	2007-01-30	Acyl deoxyribonucleoside derivatives and uses thereof
US6743782B1 (en)	2004-06-01	Acyl deoxyribonucleoside derivatives and uses thereof
AU610315B2 (en)	1991-05-16	Acyl deoxyribonucleoside derivatives and uses thereof
KR920007395B1 (ko)	1992-08-31	아실 데옥시리보뉴클레오시드 유도체 및 그의 사용
AU2004201154A1 (en)	2004-04-22	Pyrimidine Nucleotide Precursors for Treatment of Systemic Inflammation and Inflammatory Hepatitis

Legal Events

Date	Code	Title
1996-11-14	FF	Patent granted
1997-04-15	KB	Patent renewed
1999-04-11	KB	Patent renewed
2003-01-12	KB	Patent renewed
2006-12-27	KB	Patent renewed
2009-06-15	EXP	Patent expired